Loading…
Phaarmasia (BSE 523620)₹79.55−2.99%Pharmaceuticals
Phaarmasia is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 3.1 against a peer median of 10.9, and ROCE of 15.9% against a peer median of 9.1%, and latest-quarter sales growth of 42.3% against a peer median of 4.8%. By market cap it is #4 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zenith Drugs | 68 | 17.1 | 9.1 | 5.8 | 0.73 | 0.0 | 170 | 4 | 40.8 | 99.0 | vs BSE 523620 |
| Onyx Biotec | 62 | — | 1.1 | −0.4 | 0.27 | 0.0 | 69 | −0 | 9.8 | −64.6 | vs BSE 523620 |
| Sunrest Lifescience | 61 | 7.4 | 28.5 | 22.4 | 0.86 | 0.0 | 71 | 8 | — | — | vs BSE 523620 |
| Phaarmasia | 54 | 3.1 | 15.9 | 12.9 | 0.05 | 0.0 | 47 | 18 | 42.3 | — | — |
| Biofil Chemicals & Pharmaceuticals | 50 | 18.3 | 15.8 | 13.8 | 0.14 | 0.0 | 28 | 3 | −9.2 | 5.3 | vs BSE 523620 |
| Parmax Pharma | 49 | — | −82.9 | — | — | 0.0 | 12 | −4 | −31.5 | — | vs BSE 523620 |
| ANG Lifesciences India | 48 | — | −4.0 | −18.9 | 1.50 | 0.0 | 93 | −11 | −37.8 | — | vs BSE 523620 |
| Mangalam Drugs and Organics | 46 | — | −14.0 | −35.1 | 1.02 | 0.0 | 232 | −44 | −0.2 | — | vs BSE 523620 |
| Vivimed Labs | 45 | — | −65.0 | — | — | 0.0 | 70 | −176 | −53.8 | — | vs BSE 523620 |
| Vasundhara Rasayans | 44 | 7.4 | 20.2 | 15.2 | 0.04 | 1.5 | 36 | 6 | 53.1 | 441.3 | vs BSE 523620 |
| Chandra Bhagat Pharma | 43 | 14.3 | 12.1 | 9.6 | 0.50 | 0.0 | 116 | 3 | 313.6 | — | vs BSE 523620 |
| Peer median | 49 | 10.9 | 9.1 | 9.6 | 0.50 | 0.0 | 70 | 3 | 4.8 | 52.1 |
Listed companies closest to Phaarmasia in Pharmaceuticals include Zenith Drugs, Onyx Biotec, Sunrest Lifescience, Biofil Chemicals & Pharmaceuticals, Parmax Pharma, ANG Lifesciences India, Mangalam Drugs and Organics, Vivimed Labs.
Zenith Drugs, with a market cap of ₹67.72 Cr.
Phaarmasia trades at a P/E of 3.1; the median of its peer set is 10.9. A P/E above or below the median is a description, not a judgement on value.
Phaarmasia's return on capital employed is 15.9%, above the peer median of 9.1%.